Psy Therapeutics is discovering and developing novel medicines to improve the lives of people affected by central nervous system (CNS) disorders

Psy’s value-creating pipeline consists of compelling risk-balanced programs which address significant unmet needs in CNS. Each program applies tailored, cutting-edge technologies to enhance R&D productivity and deliver potentially first-in-class or best-in-class therapies.

Psy Therapeutics team of executives and neuropsychiatric leaders have a proven ability to create significant and sustained value for patients and investors

Psy’s extensive and interconnected system of long-term collaborations provide us access to highly advanced and validated drug discovery and development capabilities. This strategic network increases our R&D productivity throughout the drug development process.

Dr. Stephen J. Haggarty leads Psy Therapeutics’ Dementia program and is a fully engaged member of the Scientific Advisory Board

Recognized as one of the world’s most prominent authorities on mood and anxiety disorders, Dr. Jerry Rosenbaum is a Co-Founder of Psy Therapeutics

Want to learn more about partnering with Psy THerapeutics? Contact us and our various departments by filling out the contact us form.

Dr. Daniel Fass is a fully engaged member of Psy’s Scientific Advisory Board and an accomplished molecular neuroscientist focused on neuropsychiatric disease research

Paul J. Murphy, who served as senior litigation partner at the renowned global law firm, King & Spalding, LLP, had a career that heavily immersed him in a multitude of matters in the life sciences sector. During his tenure, Paul represented Fortune 500 and private companies across various industries in complex, high-stake “bet the company” litigation, including class actions, …

Dr. Patel brings 15 years of experience in cannabinoid neurobiology to the Psy team to develop novel treatments for major psychiatric disorders